510(k) Registration for AI Clinical Screening — What It Means and Why It Matters
Key Facts
- 510(k) registration is not FDA approval — they are different regulatory pathways with different requirements.
- Most voice biomarker AI tools have no regulatory status at all. The few that do are cleared for a single condition.
- GIA® by Scienza Health is 510(k) registered for multimodal screening across 46 cognitive, behavioral, and neurological conditions.
When a facility evaluates an AI clinical screening tool, the first question is usually “Is it FDA approved?” The answer is almost always no — because FDA approval (PMA) is not the regulatory pathway for most clinical AI software. 510(k) registration is. And the distinction matters. Most voice biomarker AI tools on the market have no regulatory status at all. The few that do are cleared for a single condition within a single clinical category. Understanding what 510(k) registration actually requires — and what it does not — is essential for any medical director or compliance officer evaluating screening technology.
What 510(k) Registration Actually Means
510(k) registration means the platform has been validated against a legally marketed predicate device through a regulatory pathway that requires demonstrated safety and effectiveness. It is not FDA approval. It is not an endorsement. It means the manufacturer has submitted evidence that the device is substantially equivalent to a device already on the market — and that adverse event reporting is a regulatory obligation, not a policy choice. For the medical director or compliance officer evaluating a clinical AI tool, 510(k) is the minimum regulatory standard that separates regulated clinical software from unregulated wellness applications. Tools without it operate outside the regulatory framework entirely.
The Voice Biomarker Regulatory Landscape
Most voice biomarker AI tools are built to screen for a single condition — depression, cognitive decline, or pulmonary function. Each addresses one clinical category using one signal type. Each requires its own session, its own documentation, its own coding. Traditional tools like the MMSE, MoCA, and PHQ-9 follow the same single-condition pattern but add 15–30 minutes of trained staff time per assessment. The regulatory landscape reflects this fragmentation: existing 510(k)-cleared voice tools cover one condition within one organ system. No single-condition tool provides a complete clinical picture from one patient interaction.
The Operator's Guide to Multimodal Clinical AI
What administrators, DONs, and regional operators need to know before evaluating clinical AI platforms. Covers EHR integration, staffing impact, reimbursement codes, and deployment timelines.
What Multimodal 510(k)-Registered Screening Looks Like
GIA® by Scienza Health is 510(k) registered and screens for 46 cognitive, behavioral, and neurological conditions in a single patient conversation lasting under 5 minutes. The platform combines voice biomarkers, computer vision, and speech analysis — multimodal, not single-signal. From 40 seconds of natural speech, GIA® analyzes 2,500+ biomarkers while simultaneously tracking facial micro-expressions and movement patterns. Structured medical notes, CPT codes, biomarker results, and session video are prepared for clinician review and submission to the EHR. The clinician authorizes every record. The platform operates under 14 governance domains with 8 verified test cases and 0 silent failures, validated across 19 peer-reviewed studies from Beth Israel Deaconess, NIH, and MIT.
Conclusion
510(k) registration is not a marketing claim. It is a regulatory obligation that governs how a clinical AI tool is built, tested, monitored, and reported on. For facilities evaluating screening technology, it is the line between regulated clinical software and everything else. See the full regulatory details. Review the governance framework.
Sources & References
- U.S. Food & Drug Administration. Premarket Notification 510(k). fda.gov
- U.S. Food & Drug Administration. AI/ML-Based Software as a Medical Device. fda.gov
- Scienza Health clinical validation: Depression 81.6%, PTSD 80.0%, Anxiety 77.5%, Parkinson’s AUC 0.97, Cognitive decline 70.8%. 12.3M patient records, 27B clinical events.
David Kaiser is the Founder and CEO of Scienza Health, where he leads the development of GIA®, a Digital Human® that screens for 46 cognitive and neurological conditions using 2,500+ speech biomarkers in under 5 minutes. The platform is 510(k) registered, HIPAA compliant, and has been validated on 12.3M patient records and 27B clinical events.
Frequently Asked Questions
What is the difference between 510(k) registration and FDA approval for clinical AI?
510(k) registration requires a manufacturer to demonstrate that a device is substantially equivalent to a legally marketed predicate device — establishing safety and effectiveness through the predicate comparison pathway. FDA approval (PMA) requires independent clinical trial data proving safety and effectiveness without a predicate comparison. Most clinical AI software, including voice biomarker screening tools, follows the 510(k) pathway. GIA® by Scienza Health is 510(k) registered for multimodal clinical screening across 46 conditions.
Is voice biomarker screening 510(k) registered?
Most voice biomarker screening tools on the market have no regulatory status. The few that hold 510(k) clearance are limited to a single condition within a single clinical category. GIA® by Scienza Health is the only 510(k)-registered voice AI platform built for multimodal, multi-condition screening — covering 46 cognitive, behavioral, and neurological conditions using voice biomarkers, computer vision, and speech analysis in a single patient conversation.
The Clinical Signal
Hear the latest episode on clinical AI screening in post-acute care.